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Abstract
Background: Our previous study has recently shown that plasma heme oxygenase-1 (HO-1), a stress-responsive protein, is
elevated in individuals with type 2 diabetes. The current study aimed to examine the association between plasma HO-1
concentration and impaired glucose regulation (IGR) in non-diabetic individuals.
Methods: We conducted a case-control study including a total of 865 subjects (262 IGR individuals and 603 healthy controls)
in a Chinese population. Basic characteristics were collected by questionnaire and standardized anthropometric
measurements. Plasma HO-1 concentration was determined by ELISA.
Results: Plasma HO-1 concentration was significantly increased in IGR individuals compared with healthy controls (1.34
(0.81–2.29) ng/ml vs 0.98 (0.56–1.55) ng/ml, P,0.001). After adjustment for age, sex, and BMI, the ORs for IGR in the highest
quartile of plasma HO-1 concentrations, compared with the lowest, was 3.42 (95% CI 2.11–5.54; P for trend ,0.001). The
trend remained significant even after additional adjustment for smoking, alcohol drinking, hypertension, family history of
diabetes, lipid profiles and C-reactive protein. In the receiver-operating characteristic curve analysis, addition of plasma HO-
1 concentration to a model with known risk factors yielded significantly improved discriminative value for IGR (area under
the curves 0.75 (95% CI 0.71–0.78) vs. 0.72 (95% CI 0.69–0.76); P for difference=0.026).
Conclusions: Elevated plasma HO-1 concentration is significantly associated with increased ORs for IGR. However, its clinical
utility should be validated in further studies, especially in prospective cohort studies.
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Introduction
Individuals with impaired glucose regulation (IGR), including
impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT), has been demonstrated to exert relatively high risk for the
future development of type 2 diabetes mellitus (T2DM) [1] as well
as cardiovascular disease (CVD) [2]. Although the pathogenesis of
IGR remains unclear, enhanced oxidative stress in the form of
lipid peroxidation and DNA oxidative damage in IGR is found in
previous studies [3,4]. In fact, oxidative stress has been implicated
in insulin resistance and beta-cell dysfunction which are essential
clinical characteristics of IGR and T2DM [3]. Heme oxygenase-1
(HMOX1 or HO-1), also termed as heat shock protein 32, is the
inducible isoform of heme oxygenase that catalyzes the NADPH-
dependent decomposition of heme to carbon monoxide (CO),
ferrous iron, and biliverdin [5]. HO-1 expression is highly
responsive to a broad spectrum of chemical and physical stress
agents, such as hydrogen peroxide, heavy metals, UVA irradia-
tion, hypoxia, hyperoxia, pro-inflammatory cytokines and heme
itself [6,7]. Therefore, HO-1 as a stress-inducible protein has been
suggested to be a sensitive and reliable marker of oxidative stress
status [6,8].
Recently, we have reported that plasma level of HO-1 is
significantly elevated in T2DM patients compared with non-
diabetic controls (including IGR individuals and healthy controls)
[9]. In addition, we have found that plasma HO-1 levels are
significantly correlated with plasma glucose concentrations (FPG
and OGTT2h), HOMA-beta, and HOMA-IR [9], which makes us
think whether plasma HO-1 levels are significantly increased in
non-diabetic individuals with moderate hyperglycemia but under
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32223the cut-point of diabetes diagnosis. Similar elevation of circulating
HO-1 levels has also been found in CVD [10,11] and other chronic
diseases [12,13,14]. However, the association between plasma HO-
1 concentration and IGR has not yet been investigated.
Thus, in this study, we aimed to assess the association between
plasma HO-1 concentration and IGR without or with adjustment for
known risk factors for IGR. Additionally, we compared the dis-
criminative value of models for IGR without or with plasma HO-1.
Methods
Study population
A total of 865 participants, including 262 IGR individuals and
603 healthy controls, were recruited for the current study. Some of
these participants are included in our previous study [9] as non-
diabetic controls. IGR individuals were consecutively recruited
from those attending the outpatient clinics of Department of
Endocrinology of Tongji Hospital affiliated to Tongji Medical
College during the period of December 2004 to December 2007.
Healthy controls were drawn from an unselected group of
population that underwent for a routine health examination in
the same hospital during the same period. IGR, including impaired
fasting glucose (IFG) and impaired glucose tolerance (IGT), was
diagnosed in accordance with the criteria recommended by World
Health Organization in 2006 incorporating both fasting plasma
glucose (FPG) and a 2-h oral glucose tolerance test (OGTT)
[15]. IFG was defined as 6.1 mmol/L#FPG,7.0 mmol/L and
OGTT2h,7.8 mmol/L; IGT was defined as FPG,7.0 mmol/L
and 7.8 mmol/L#OGTT2h,11.1 mmol/L; and healthy control
was defined as FPG,6.1 mmol/L and OGTT2h,7.8 mmol/L.
Forboth theIGRcasesandcontrols,we restrictedthestudysubjects
to only individuals who were aged $30 years, BMI,40 kg/m
2,n o
early history of diagnosed diabetes, nor any other clinically systemic
diseases, acute or chronic inflammatory diseases, acute respiratory
infection, known cardiovascular disease or cancer. The study
protocol was approved by Medical Ethics Committee of Tongji
Medical College according to the declaration of Helsinki and
written informed consent was obtained from all individuals.
As previously described [4,9], information about age, sex,
smoking, alcohol drinking, hypertension, and family history of
diabetes in their first-degree relatives were collected by question-
naire survey. Anthropometric measurements including height (m),
weight (kg) and blood pressure (mmHg) were performed using
standardized techniques. Body mass index (BMI) was calculated as
weight (kg)/square of height (m
2).
Laboratory Measurements
Antecubital venous blood samples were drawn into heparinized
tubes from all the participants in the morning after an overnight
fast. The participants were asked to sit in the upright position to
ensure minimal venous occlusion time. For the OGTT test, 75 g
oral glucose dissolved in 250 to 300 ml water were asked to be
consumed in no more than 5 minutes. Plasma samples were
separated and retained for analysis of biochemical parameters,
including fasting plasma glucose (FPG), fasting plasma insulin
(FPI), 2-h post-glucose load (OGTT2h), total cholesterol (TC),
triglycerides (TG) and high-density lipoprotein cholesterol (HDL-
C), as previously described [9]. Intra- and inter-assay coefficients
of variation were ,4% for all these assays. Homeostasis model
assessment of beta cell function (HOMA-beta) and insulin
resistance (HOMA-IR) were employed to assess the status of
insulin secretion and insulin action, respectively. HOMA-
beta=206FPI (mU/ml)/[FPG (mmol/L)-3.5], HOMA-IR=FPG
(mmol/L)6FPI (mU/ml)/22.5 [16].
Plasma HO-1 and C-reactive protein (CRP) concentration were
determined by Human HO-1 ELISA Kit (EKS-800, Stressgen/
Assay Designs, Ann Arbor, MI, USA) and Human CRP
Quantikine ELISA kit (SCRP00, R&D Systems, Minneapolis,
MN, USA), respectively. The intra-assay and inter-assay coeffi-
cients of variation of these kits have been determined to be ,10%.
Statistical analysis
Statistical analyses were performed using Stata 11.0 (Stata
Corp., College Station, TX, USA). Descriptive statistics were
calculated for all demographic and clinical characteristics of the
study subjects. Comparisons between IGR cases and controls were
performed by Chi-square (categorical variables), t test (continuous
variables, normal distribution) or Mann-Whitney U test (contin-
uous variables, skewed distribution).
Multivariate logistic regression analysis was used to evaluate the
independent association of plasma HO-1 concentration with the
likelihood of IGR. Hosmer-Lemeshow goodness-of-fit tests were
used to evaluate the appropriate model fit. For calculation of the
odds ratios (ORs) for IGR, plasma HO-1 concentrations were
categorized in quartiles according to the control group: category 1,
,0.56 ng/ml; category 2, 0.56–0.98 ng/ml, category 3, 0.98–
1.55 ng/ml and category 4, $1.55 ng/ml. Crude and adjusted
ORs for IGR were calculated, respectively. To estimate the
discriminative value of plasma HO-1 concentrations on IGR,
receiver-operating characteristic (ROC) curves were plotted and
corresponding areas under the curve (AUC) were compared using
a model with known risk factors (Model A, including age, sex,
BMI, alcohol consumption, smoking, hypertention and family
history of diabetes) and another model with plasma HO-1
concentrations added in (Model B, including Model A Plus HO-1).
All reported P values were 2-sided and P,0.05 was considered
to be statistically significant.
Results
Demographic and clinical characteristics of the study
subjects
As shown in Table 1, the individuals with IGR, compared to
healthy controls, had higher body mass index (BMI), higher
prevalence of hypertension and family history of diabetes, higher
levels of FPG, OGTT2h, HOMA-IR, TG and CRP, and lower
levels of HOMA-beta and HDL-C.
Association between plasma HO-1 levels and odds of IGR
Plasma HO-1 concentration was significantly increased in
individuals with IGR compared with controls (Median (inter-
quartile range, IQR) 1.34 (0.81–2.29) ng/ml vs 0.98 (0.56–1.55)
ng/ml, respectively; P,0.001) (Figure 1).
In the logistic regression analysis, we observed increased ORs
for IGR associated with higher level of the plasma HO-1 (Table 2).
Individuals in the highest quartile of plasma HO-1 levels had a
significantly increased ORs compared with those in the lowest
quartile (crude OR 3.45, 95% confidence interval (CI) 2.19–5.42,
P for trend ,0.001). Adjustment for age, sex and BMI (adjusted
OR 3.42, 95% CI 2.11–5.54; P for trend ,0.001; Model 1) or
further adjustment for smoking, alcohol drinking, hypertension
and family history of diabetes (adjusted OR 3.39, 95% CI 2.08–
5.54; P for trend ,0.001; Model 2) did not alter the results. The
trend remained significant even after additional adjustment for
lipid profiles (adjusted OR 3.29, 95% CI 2.00–5.43; P for trend
,0.001; Model 3) and further C-reactive protein (adjusted OR
3.12, 95% CI 1.89–5.16; P for trend ,0.001; Model 4).
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I nt h eR O Cc u r v e sf r o mt h el o g i s t i cr e g r e s s i o nm o d e l s ,w e
first compared the AUCs for IGR using plasma HO-1 levels
(continuous variable) with HO-1 categories (categorical vari-
able), and we found that the model using plasma HO-1 levels
yielded higher AUC for IGR than plasma HO-1 categories
(AUC 0.64 (0.60–0.68) and 0.62 (0.58–0.66), respectively;
Table 1. Demographical and Clinical Characteristics of the Study Subjects.
Characteristics IGR Cases Controls P Value
Number of Subjects 262 603
Age, years 50.11 (11.8) 49.83 (10.02) 0.737
Male, n (%) 141 (53.82) 361 (59.87) 0.100
BMI, kg/m
2 25.00 (23.31–26.73) 23.23 (21.30–24.98) ,0.001
Smoking, n (%) 61 (23.28) 207 (34.33) 0.001
Alcohol, n (%) 58 (22.14) 194 (32.17) 0.003
Family History of Diabetes, n (%) 39 (14.89) 35 (5.80) ,0.001
Hypertention, n (%) 85 (32.44) 135 (22.39) 0.002
FPG (mmol/L) 5.97 (0.64) 4.81 (0.66) ,0.001
FPI (mU/ml) 9.60 (6.68–13.16) 6.52 (4.76–8.52) ,0.001
OGTT2h (mmol/L) 9.22 (8.45–10.12) 7.47 (7.09–7.76) ,0.001
HbA1c (%) 5.89 (0.57) 5.50 (0.33) ,0.001
HOMA-beta 80.69 (50.55–119.67) 100.25 (71.71–137.38) ,0.001
HOMA-IR 2.52 (1.70–3.67) 1.40 (0.94–1.87) ,0.001
TC (mmol/L) 4.40 (3.67–5.16) 4.36 (3.87–4.95) 0.522
TG (mmol/L) 1.41 (1.00–1.97) 1.08 (0.67–1.53) ,0.001
HDL-C (mmol/L) 1.22 (1.07–1.44) 1.28 (1.13–1.46) 0.040
CRP (ng/ml) 12.01 (4.47–22.75) 8.55 (3.97–14.61) ,0.001
Abbreviations: IGR, impaired glucose regulation; BMI, body mass index; FPG, fasting plasma glucose; FPI, fasting plasma insulin; OGTT2h, 2-h post-glucose load; HOMA-
beta, homeostasis model assessment of beta cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C,
high-density lipoprotein cholesterol; CRP, C-reactive protein.
Data are presented as number (percentage) for categorical data, mean (standard deviation) for parametrically distributed data or median (interquartile range) for
nonparametrically distributed data.
doi:10.1371/journal.pone.0032223.t001
Figure 1. Plasma HO-1 concentrations in IGR individuals and controls. Plasma HO-1 concentration was significantly increased in individuals
with IGR compared with controls (1.34 (0.81–2.29) ng/ml vs 0.98 (0.56–1.55) ng/ml, respectively; P,0.001).
doi:10.1371/journal.pone.0032223.g001
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in the next step comparison between models without and with
plasma HO-1, we chose plasma HO-1 levels in the form of
continuous variable.
As shown in Figure 3, the AUC for a model with known risk
factors (Model A), comprising age, sex, BMI, alcohol consump-
tion, smoking, hypertention and family history of diabetes, was
0.72 (95% CI 0.69–0.76) for IGR. However, when plasma HO-1
concentration was added to the model (Model B, including
Model A plus HO-1), the AUC was significantly increased to
0.75 (95% CI 0.71–0.78; P=0.026 for the difference of the
AUCs).
Discussion
The current study indicates that plasma HO-1 concentration is
elevated in individuals with IGR in comparison with healthy
controls, and it is significantly associated with odds of IGR. The
association between plasma HO-1 concentrations and IGR retains
rather consistent under adjustment for possible confounding
factors including age, sex, BMI, smoking, alcohol drinking,
hypertension, family history of diabetes, lipid profiles and CRP,
which makes plasma HO-1 more convincing as an emerging
independent marker for IGR.
IGR, also referred to pre-diabetes, has been recognized as a
metabolic intermediate state between a ‘‘normal’’ state and T2DM
Table 2. Odds Ratios (95% CI) of IGR Prevalence, by Quartile of Plasma HO-1 Levels.
Variable Quartile of Plasma HO-1 Levels
P Value for
Trend
1 (Lowest) 2 3 4 (Highest)
Plasma HO-1 Levels, ng/ml ,0.56 0.56–0.98 0.98–1.55 $1.55 /
Cases/Controls, n/n 32/150 54/152 65/150 111/151 /
Crude OR (95% CI) 1 1.67 (1.02–2.72) 2.03 (1.26–3.28) 3.45 (2.19–5.42) ,0.001
Adjusted OR (95% CI), Model 1 1 1.95 (1.16–3.29) 2.37 (1.42–3.93) 3.42 (2.11–5.54) ,0.001
Adjusted OR (95% CI), Model 2 1 1.92 (1.13–3.27) 2.29 (1.36–3.86) 3.39 (2.08–5.54) ,0.001
Adjusted OR (95% CI), Model 3 1 1.95 (1.14–3.34) 2.36 (1.40–3.98) 3.29 (2.00–5.43) ,0.001
Adjusted OR (95% CI), Model 4 1 1.95 (1.13–3.35) 2.32 (1.37–3.93) 3.12 (1.89–5.16) ,0.001
Results from multivariate Logistic regression analysis are presented using the combined data from the two-phase independent study.
Model 1, adjusted for age, sex, and BMI;
Model 2, adjusted for Model 1, smoking, alcohol drinking, hypertension and family history of diabetes;
Model 3, adjusted for Model 2, TC, TG and HDL-C;
Model 4, adjusted for Model 3, CRP.
doi:10.1371/journal.pone.0032223.t002
Figure 2. ROC curves and corresponding AUCs for IGR using plasma HO-1 levels or HO-1 categories. The AUCs for plasma HO-1 levels
and HO-1 categories were 0.64 (0.60–0.68) and 0.62 (0.58–0.66), respectively; P=0.0006 for the difference of the AUCs. Plasma HO-1 concentrations
were categorized in quartiles according to the healthy control group as follows: category 1, ,0.56 ng/ml; category 2, 0.56–0.98 ng/ml, category 3,
0.98–1.55 ng/ml and category 4, $1.55 ng/ml.
doi:10.1371/journal.pone.0032223.g002
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and reversible properties. IGR people shows approximately 10-
fold higher risk of T2DM [1], and on the other hand, the onset of
T2DM in individuals with IGR can be delayed or prevented
through lifestyle modifications [18,19]. Therefore, it is crucial to
elucidate the underlying mechanisms of IGR and to develop
biomarkers to understand the role of corresponding mechanisms
in human.
Under high glucose exposure, HO-1 gene expression and
enzyme activities in the islets are elevated remarkably in parallel
with hyperglycemia-induced intracellular peroxide levels [20,21],
prior to the elevation of classical antioxidant enzymes (e.g.,
superoxide dismutase, catalase and glutathione peroxidase) [22].
In addition, HO-1 mediates the anti-inflammatory effect of
interleukin-10 through a p38 mitogen-activated protein kinase-
dependent pathway [23].
Recently, it has been found that HO-1 is present and
detectable in serum or plasma samples and serves as a systemic
stress marker [12,24]. Elevated circulating HO-1 levels are
subsequently found in several oxidative stress-related illness
conditions, such as in chronic silicosis [12], T2DM [9], acute
myocardial infarction [11], coronary microvascular dysfunction
[10], Parkinson’s disease [13], and critically ill patients [14].
Similar to our previous report [9], we found that plasma HO-1
concentrations were significantly correlated with fasting plasma
glucose, 2 hour OGTT glucose, HOMA-beta and HOMA-IR in
this population. Taken together with our previous study [9], the
study shows an association that could suggest that HO-1 is
responsive to high blood glucose, even if under moderate
hyperglycemia in the form of IGR. The current study also
suggests that plasma HO-1 concentration can significantly
improve the discriminative value for IGR. If the utility of HO-
1 be confirmed in prospective cohort studies, it might be
incorporated into established panel of biomarkers [25] to help
further improve the predictive value for IGR and T2DM.
There are several limitations to this study. First, the current case-
control study design could not allow examining the causal
relationship between plasma HO-1 and IGR, which remains to
be confirmed in further prospective cohort studies. We also cannot
directly evaluate the predictive value for IGR, thus we only evaluate
the discriminative value instead. Second, we did not have
information on diet and physical activity among the participants,
while it is possible that individuals with IGR have a different dietary
and exercise habits compared to controls. Whether such difference
confounds our results remains unknown. Third, since it has been
demonstrated that changes in 2-h postload glucose develops years
prior to worsening in fasting glucose [26], IFG and IGT might
represent not only different types of glucose abnormality, but also
differentstagesalongthesameline ofabnormality.However,wedid
not perform a separate analysis for IFG group and IGT group,
because there were only 21 IFG subjects (8%) in our IGR cases
group. Whether there is a significant difference in association
between HO-1-IFG and HO-1-IGT merits further investigation.
Fourth, diabetic comorbidities may occur in a small portion of
patients with prediabetes. Although we excluded those with known
cardiovascular disease, it was difficult to eliminate potential bias
because elevated circulating HO-1 levels may be a result of diabetic
comorbidities. Fifth, all participants in this study were of Chinese
Han ethnicity, which minimizes the confounding effects by ethnic
background. Whether these results can be generalized to other
populations need to be studied further.
In conclusion, elevated plasma HO-1 concentration is signifi-
cantly associated with increased ORs for IGR. However, its
clinical utility should be validated in further studies, especially in
prospective cohort studies.
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